Skip to main content

An Oklahoma judge on Monday found Johnson & Johnson and its subsidiaries helped fuel the state’s opioid crisis and ordered the consumer products giant to pay US$572 million, more than twice the amount another drug manufacturer agreed to pay in a settlement.

Cleveland County District Judge Thad Balkman’s ruling followed the first state opioid case to make it to trial and could help shape negotiations over roughly 1,500 similar lawsuits filed by state, local and tribal governments consolidated before a federal judge in Ohio.

“The opioid crisis has ravaged the state of Oklahoma,” Justice Balkman said before announcing the verdict. “It must be abated immediately.”

Story continues below advertisement

The companies are expected to appeal the ruling to the Oklahoma Supreme Court.

Before Oklahoma’s trial began May 28, the state reached settlements with two other defendant groups – a US$270-million deal with OxyContin-maker Purdue Pharma LP and an US$85-million settlement with Israeli-owned Teva Pharmaceutical Industries Ltd.

Oklahoma argued the companies and their subsidiaries created a public nuisance by launching an aggressive and misleading marketing campaign that overstated how effective the drugs were for treating chronic pain and understated the risk of addiction. Oklahoma Attorney-General Mike Hunter says opioid overdoses killed 4,653 people in the state from 2007 to 2017.

Mr. Hunter has called Johnson & Johnson a “kingpin” company that was motivated by greed. He specifically pointed to two former Johnson & Johnson subsidiaries, Noramco and Tasmanian Alkaloids, which produced much of the raw opium used by other manufacturers to produce the drugs.

On Monday, Mr. Hunter said the Oklahoma case could provide a “roadmap” for other states to follow in holding drug makers responsible for the opioid crisis.

“That’s the message to other states: We did it in Oklahoma. You can do it elsewhere,” Mr. Hunter said. “Johnson & Johnson will finally be held accountable for thousands of deaths and addictions caused by their activities.”

“They’ve been the principal origin for the active pharmaceutical ingredient in prescription opioids in the country for the last two decades,” Mr. Hunter said after the trial ended July 15. “It is one of the most important elements of causation with regard to why the defendants … are responsible for the epidemic in the country and in Oklahoma.”

Story continues below advertisement

Lawyers for the company have maintained they were part of a lawful and heavily regulated industry subject to strict federal oversight, including the U.S. Drug Enforcement Agency and the Food and Drug Administration, during every step of the supply chain. Lawyers for the company said the judgment was a misapplication of public nuisance law.

Sabrina Strong, a lawyer for Johnson & Johnson and its subsidiaries, said the companies have sympathy for those who suffer from substance abuse, but called the judge’s decision “flawed.”

“You can’t sue your way out of the opioid abuse crisis,” Ms. Strong said. “Litigation is not the answer.”

Oklahoma pursued the case under the state’s public nuisance statute and presented the judge with a plan to abate the crisis that would cost between US$12.6-billion for 20 years and US$17.5-billion over 30 years. Lawyers for Johnson & Johnson have said that estimate is wildly inflated.

Also on Monday, the Kentucky Supreme Court declined to review an earlier ruling, making previously secret testimony from former Purdue Pharma president Rickard Sackler and other documents public. The court record was sealed in 2015 as part of a US$24-million settlement between Purdue and Kentucky.

The 17 million pages of documents were being shipped Monday from Frankfort to Pike County, where the case originated. The Pike County Circuit Court Clerk’s office could not immediately say how and when they would be available.

Story continues below advertisement

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter